添加epcoritamab 于R2治疗显著改善了复发性毛囊淋巴瘤患者的治疗结果,导致FDA在2025年11月批准. Adding epcoritamab to R2 therapy significantly improved outcomes for relapsed follicular lymphoma patients, leading to FDA approval in November 2025.

一项3期试验显示,在复发性或耐药性小胞性淋巴瘤患者中,添加epcoritamab与rituximab和lenalidomide (R2) 显著改善了无进展的生存率和反应率,疾病进展或死亡风险降低了79%. A phase 3 trial showed that adding epcoritamab to rituximab and lenalidomide (R2) significantly improved progression-free survival and response rates in patients with relapsed or refractory follicular lymphoma, with a 79% reduction in disease progression or death risk. 经过14.8个月的中位跟踪后,16个月的PFS为85.5%,与40.2%相比,仅R2为40.2%,完整答复率达到83%,与50%相比为50%。 After a median follow-up of 14.8 months, 16-month PFS was 85.5% with the combination versus 40.2% with R2 alone, and complete response rates reached 83% compared to 50%. 2025年11月,林业发展局对这种无化疗的门诊治疗方案给予全面批准,该治疗方案现已被视为新的护理标准。 The FDA granted full approval in November 2025 for this chemotherapy-free, outpatient regimen, now considered a new standard of care.